ATE515508T1 - Verbindungen für die die zellmembran im wesentlichen undurchlässig ist und ihre anwendung - Google Patents
Verbindungen für die die zellmembran im wesentlichen undurchlässig ist und ihre anwendungInfo
- Publication number
- ATE515508T1 ATE515508T1 AT00965636T AT00965636T ATE515508T1 AT E515508 T1 ATE515508 T1 AT E515508T1 AT 00965636 T AT00965636 T AT 00965636T AT 00965636 T AT00965636 T AT 00965636T AT E515508 T1 ATE515508 T1 AT E515508T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- application
- cell membrane
- essentially impermeable
- arsenoxide
- Prior art date
Links
- 210000000170 cell membrane Anatomy 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- JRIGVWDKYXCHMG-UHFFFAOYSA-N (5-arsoroso-2-hydroxyphenyl)azanium;chloride Chemical compound Cl.NC1=CC([As]=O)=CC=C1O JRIGVWDKYXCHMG-UHFFFAOYSA-N 0.000 abstract 2
- 229950008475 oxophenarsine Drugs 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/66—Arsenic compounds
- C07F9/70—Organo-arsenic compounds
- C07F9/72—Aliphatic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/66—Arsenic compounds
- C07F9/70—Organo-arsenic compounds
- C07F9/74—Aromatic compounds
- C07F9/78—Aromatic compounds containing amino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/66—Arsenic compounds
- C07F9/70—Organo-arsenic compounds
- C07F9/80—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ2967A AUPQ296799A0 (en) | 1999-09-20 | 1999-09-20 | A cell-membrane impermeable trivalent organoarsenical derivative and use thereof |
| PCT/AU2000/001143 WO2001021628A1 (en) | 1999-09-20 | 2000-09-20 | A substantially cell membrane impermeable compound and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE515508T1 true ATE515508T1 (de) | 2011-07-15 |
Family
ID=3817132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00965636T ATE515508T1 (de) | 1999-09-20 | 2000-09-20 | Verbindungen für die die zellmembran im wesentlichen undurchlässig ist und ihre anwendung |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7074766B1 (de) |
| EP (1) | EP1228076B1 (de) |
| JP (1) | JP4707294B2 (de) |
| AT (1) | ATE515508T1 (de) |
| AU (1) | AUPQ296799A0 (de) |
| CA (1) | CA2385322C (de) |
| ES (1) | ES2366467T3 (de) |
| WO (1) | WO2001021628A1 (de) |
| ZA (1) | ZA200202272B (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ296799A0 (en) | 1999-09-20 | 1999-10-14 | Unisearch Limited | A cell-membrane impermeable trivalent organoarsenical derivative and use thereof |
| AUPR379801A0 (en) * | 2001-03-19 | 2001-04-12 | Unisearch Limited | Use of a substantially cell membrane impermeable compound for treating arthritis |
| AUPR598901A0 (en) * | 2001-06-28 | 2001-07-19 | Unisearch Limited | Inhibition of angiogenesis by targeting protein tyrosine phosphatases |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| AUPR874601A0 (en) | 2001-11-08 | 2001-11-29 | Unisearch Limited | Selective targeting of apoptotic cells |
| EP1474128B1 (de) * | 2002-01-07 | 2016-06-01 | Board Of Regents, The University Of Texas System | S-dimethylarsino-thiosuccinsäure,s-dimethylarsino-2-thiobenzoesäure, s-(dimethylarsino)-glutathion zur krebsbehandlung |
| AU2008200304B2 (en) * | 2002-11-07 | 2012-02-02 | Newsouth Innovations Pty Limited | Induction of the mitochondrial permeability transition |
| EP1563099B1 (de) * | 2002-11-07 | 2009-07-22 | Newsouth Innovations Pty Limited | Induktion der mitochondrialen permeabilitätstransition |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| EP2975135A1 (de) | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glykopegylierter Faktor IX |
| TW200829261A (en) * | 2006-09-29 | 2008-07-16 | Ziopharm Oncology Inc | Method for controlling angiogenesis in animals |
| EP2069371B1 (de) * | 2006-11-01 | 2013-03-13 | NewSouth Innovations Pty Limited | Organo-arsenoxid-verbindungen und deren verwendung |
| KR102055873B1 (ko) | 2007-07-09 | 2019-12-13 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
| WO2009043114A1 (en) * | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Arsenoxide compound and method of use |
| WO2016061618A1 (en) * | 2014-10-24 | 2016-04-28 | Newsouth Innovations Pty Limited | Selective targeting of procoagulant platelets |
| WO2020206503A1 (en) | 2019-04-12 | 2020-10-15 | Centenary Institute Of Cancer Medicine And Cell Biology | Conjugates and their use as imaging agents |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2370092A (en) * | 1942-05-04 | 1945-02-20 | Parke Davis & Co | Organic amine derivatives and method of obtaining same |
| US2409291A (en) * | 1942-05-19 | 1946-10-15 | Squibb & Sons Inc | Chemotherapeutic sulfanilamide derivatives |
| US2465308A (en) * | 1946-11-27 | 1949-03-22 | Hoffmann La Roche | Arsenoso compounds and method of preparation |
| US2664432A (en) * | 1947-01-28 | 1953-12-29 | Ernst A H Friedheim | Heterocyclic metal and sulfur organic compounds |
| US2553515A (en) * | 1948-12-11 | 1951-05-15 | Hoffmann La Roche | N-(p-arsenoso-benzyl)-urea |
| US2951766A (en) * | 1957-07-15 | 1960-09-06 | Le Roy A White | Antiseptic plastic |
| FR2013455A1 (en) * | 1968-07-22 | 1970-04-03 | Erasme | Organo arsenic or organo antimony peni - cillins |
| BE786573A (fr) | 1971-07-20 | 1973-01-22 | Hoechst Ag | Medicament a base de composes arsenicaux organiques et de derives du benzimidazole |
| JPS53124606A (en) * | 1977-04-04 | 1978-10-31 | Sankyo Co Ltd | Purification of albumin |
| FR2640269B1 (fr) * | 1988-12-13 | 1991-03-15 | Maes Ludo | Composes organometalliques, leurs modes de preparation et compositions pharmaceutiques les contenant |
| US5270196A (en) | 1989-10-20 | 1993-12-14 | Bristol-Myers Squibb Company | Arylsulfatase from streptomyces |
| FR2684382B1 (fr) * | 1991-12-02 | 1994-10-21 | Rhone Merieux | Medicaments et preparations pures de dichlorhydrate de melarsomine, leur procede d'obtention et produits intermediaires obtenus. |
| WO1998051297A1 (en) | 1997-05-14 | 1998-11-19 | The University Of New Mexico | Inhibition of cell surface protein disulfide isomerase |
| US6875451B2 (en) | 1997-10-15 | 2005-04-05 | Polarx Biopharmaceuticals Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| FR2781674B1 (fr) | 1998-07-31 | 2002-06-28 | Inst Nat Sante Rech Med | Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons |
| CA2349444A1 (en) | 1998-11-03 | 2000-05-11 | Mitokor | Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| US6191123B1 (en) | 1999-03-19 | 2001-02-20 | Parker Hughes Institute | Organic-arsenic compounds |
| EP1210596A2 (de) | 1999-06-22 | 2002-06-05 | Mitokor | Verfahren zur untersuchung subzellulärer zustände mit hilfe von energietransfer |
| AUPQ296799A0 (en) | 1999-09-20 | 1999-10-14 | Unisearch Limited | A cell-membrane impermeable trivalent organoarsenical derivative and use thereof |
| AUPR379801A0 (en) * | 2001-03-19 | 2001-04-12 | Unisearch Limited | Use of a substantially cell membrane impermeable compound for treating arthritis |
| AUPR874601A0 (en) | 2001-11-08 | 2001-11-29 | Unisearch Limited | Selective targeting of apoptotic cells |
-
1999
- 1999-09-20 AU AUPQ2967A patent/AUPQ296799A0/en not_active Abandoned
-
2000
- 2000-09-20 WO PCT/AU2000/001143 patent/WO2001021628A1/en not_active Ceased
- 2000-09-20 ES ES00965636T patent/ES2366467T3/es not_active Expired - Lifetime
- 2000-09-20 CA CA2385322A patent/CA2385322C/en not_active Expired - Fee Related
- 2000-09-20 AT AT00965636T patent/ATE515508T1/de not_active IP Right Cessation
- 2000-09-20 EP EP00965636A patent/EP1228076B1/de not_active Expired - Lifetime
- 2000-09-20 JP JP2001525003A patent/JP4707294B2/ja not_active Expired - Fee Related
- 2000-09-20 US US10/088,540 patent/US7074766B1/en not_active Expired - Fee Related
-
2002
- 2002-03-20 ZA ZA200202272A patent/ZA200202272B/en unknown
-
2006
- 2006-05-22 US US11/419,651 patent/US7674775B2/en not_active Expired - Fee Related
- 2006-05-22 US US11/419,644 patent/US7498406B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1228076B1 (de) | 2011-07-06 |
| JP2003509516A (ja) | 2003-03-11 |
| ZA200202272B (en) | 2003-07-25 |
| WO2001021628A1 (en) | 2001-03-29 |
| CA2385322A1 (en) | 2001-03-29 |
| US7674775B2 (en) | 2010-03-09 |
| EP1228076A1 (de) | 2002-08-07 |
| US7498406B2 (en) | 2009-03-03 |
| AUPQ296799A0 (en) | 1999-10-14 |
| ES2366467T3 (es) | 2011-10-20 |
| US20070037995A1 (en) | 2007-02-15 |
| US7074766B1 (en) | 2006-07-11 |
| HK1048818A1 (en) | 2003-04-17 |
| US20070037996A1 (en) | 2007-02-15 |
| CA2385322C (en) | 2011-01-25 |
| JP4707294B2 (ja) | 2011-06-22 |
| EP1228076A4 (de) | 2002-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE515508T1 (de) | Verbindungen für die die zellmembran im wesentlichen undurchlässig ist und ihre anwendung | |
| TR200102800T2 (tr) | Yeni bileşikler. | |
| DE60214392D1 (de) | 1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen | |
| AU7278500A (en) | Fungicides | |
| TR200800474T2 (tr) | Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem. | |
| TR200200225T2 (tr) | İkameli okzo azahetrosiklil bileşikleri | |
| FR2848850B1 (fr) | Nouvelles compositions de particules magnetiques recouvertes de derives gem-bisphosphonates. | |
| DE69626218D1 (de) | 4-pyrimidinyl- or 4-pyrazinyl-piperazinyl-phenyl-oxazolidinon derivate, deren herstellung und deren verwendung als antibakterielle mittel | |
| MXPA02011370A (es) | Iminoazinas substituidas. | |
| TR200001012T2 (tr) | Yeni ariloksi-alkil-dialkilaminler. | |
| IT1271325B (it) | Composti diastereomericamente puri derivati da 3-oxo e 3-tioxo-4-azaandrostani e loro uso come antiandrogeni | |
| ATE201195T1 (de) | Tricyclische verbindungen | |
| ATE266030T1 (de) | 1,4,7,10-tetraazabicyclo(8.2.2)tetradecan-2-on, verfahren zu ihrer herstellung und ihrer verwendung für die herstellung von tetraazamacrocyclen | |
| TW200606581A (en) | A chemically amplified positive resist composition, a haloester derivative and a process for producing the same | |
| DE50208918D1 (de) | 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung | |
| DE10347385A1 (de) | Umgelagerte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer | |
| TR200201683T2 (tr) | İkameli fenil-piperazin türevleri, bunların hazırlanması ve kullanımları | |
| PE84299A1 (es) | Compuestos policiclicos parcialmente hidrogenados | |
| NO981393L (no) | Guanidinoproteasehemmere | |
| MXPA01003633A (es) | Precursores de fragancia. | |
| WO2003035651A3 (fr) | Derives de l'artemisinine, et leurs utilisations dans le traitement du paludisme | |
| TR200200347T2 (tr) | 1,4-İkameli 4,4-diaril sikloheksanlar. | |
| WO2003080631A3 (en) | Plasma carboxypeptidase b inhibitors | |
| TR200001819T2 (tr) | COPD tedavi yöntemi. | |
| TR199800210T2 (xx) | Didepsipeptid temelli endoparazitisid kompozisyonlar, yeni didepsipeptidler ve bunlar�n �retimi i�in i�lemler. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |